Analysts expect Revvity to report Q2 2026 revenue of approximately $703.2 million and adjusted EPS of $1.23, with the stock currently trading near $112.52 against a consensus price target of $117.13. Investors are primarily focused on the company's organic revenue growth, particularly as it navigates significant demand headwinds in its China market and broader pharmaceutical sector spending.
While top-line growth remains pressured by challenging macroeconomic conditions, Revvity has maintained a perfect beat rate over the last quarter, signaling effective execution on margin discipline. The market will be closely watching for updates on the divestiture of its China Immunodiagnostics business and the integration of AI-driven informatics platforms intended to stabilize long-term growth.